#47 Mindbloom: On Psychedelics and Democratizing Access to Psychedelic Therapy | Jack Swain, Head of Clinical Operations

“The research around psychedelics is just unreal; the potential of these medicines to completely transform the way that we provide mental health care and help people who really need big changes in their life is really exciting.” – Jack Swain 

Jack Swain is Head of Clinical Operations at Mindbloom, a mental health and wellbeing company focused on psychedelic therapy. Before joining Mindbloom, Jack Swain was a healthcare consultant at The Chartis Group, where he worked with the Cleveland Clinic and Michigan Medicine.

Show notes with links, quotes, and a transcript of the episode: https://www.danielscrivner.com/notes/jack-swain1-outlier-academy-show-notes

Chapters in this interview:

• Jack’s background and intro to Mindbloom
• How healthcare today is broken, and why Jack is hopeful that it will improve
• What is psychedelic therapy?
• Why Mindbloom is focused on treating depression and anxiety
• Progress in the world of psychedelic medicine
• Examples of successful treatment with Mindbloom
• Mindbloom's treatment model and clinicians
• Scaling a telemedicine company
• The history of psychedelic medicine
• The importance of journaling in mental health therapy
• The data and research coming from Mindbloom 

Sign up here for Outlier Debrief, our weekly newsletter that highlights the latest episode, expands on important business and investing concepts, and contains the best of what we read each week.

Follow Outlier Academy on Twitter: https://twitter.com/outlieracademy.

If you loved this episode, please share a quick review on Apple Podcasts.

Learn more about your ad choices. Visit megaphone.fm/adchoices